CORT Crosses Above Average Analyst Target Monday, September 25, 8:37 AM ET, by Market News Video Staff In recent trading, shares of Corcept Therapeutics Inc (CORT) have crossed above the average analyst ...
In trading on Wednesday, shares of Par Pharmaceutical Companies Inc (PRX) crossed above their 200 day moving average of $31.16, changing hands as high as $31.96 per share. Par Pharmaceutical Companies Inc shares are currently trading up about 2.2% on the day. The chart below shows the one year performance of PRX shares, versus its 200 day moving average:
Looking at the chart above, PRX's low point in its 52 week range is $24.85 per share, with $39.57 as the 52 week high point — that compares with a last trade of $31.45.
PRX operates in the Drugs & Pharmaceuticals sector, among companies like Corcept Therapeutics Inc (NASDAQ:CORT) which is up about 1.3% today, and Cadence Pharmaceuticals Inc (CADX) trading higher by about 1.4%. Below is a three month price history chart comparing the stock performance of PRX, versus CORT and CADX.
The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors —
anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset
allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors,
commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow
the performance trail wherever it leads us.
This Article's Word Cloud:CADXCORTChannelCompaniesCrossingDrugsFinderPharmaceuticalPharmaceuticalsPortfolioStartTheirTherapeuticsTrialWednesdayaboutaboveallowsassetaveragechangingchartcommoditiescurrentlydesignedflexibilityheldhighhistorylevelmakesmovingotherperformancepointportfolioprogramregionssectorsharesharesstocksthattradingversusweekwhatwhereverwhichwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.